Showing results (161-170 of 210) with videos related to

Sort By:
Pageof 21
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
European Journal of Haematology|February 14, 2025
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported OutcomesAurore Perrot, Thierry Facon, Torben Plesner, et al.
The Lancet. Haematology|October 4, 2023
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised studyMeletios Athanasios Dimopoulos, Vania T M Hungria, Atanas Radinoff, et al.
Blood|December 28, 2020
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data setAjai Chari, Mehmet Kemal Samur, Joaquin Martinez-Lopez, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Blood Cancer Discovery|February 13, 2026
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapyJan H Frenking, Christine Riedhammer, Thomas Hielscher, et al.
Leukemia|January 15, 2025
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA studyPhilippe Moreau, Thierry Facon, Saad Z Usmani, et al.
Leukemia|September 25, 2024
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)María-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Current Medical Research and Opinion|July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myelomaLuciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
Blood Cancer Journal|July 30, 2025
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.
Pageof 21